SMITHFIELD, R.I. (AP) — Malik Grant rushed for 204 yards and three touchdowns and Rhode Island beat Bryant 35-21 on Saturday to capture its first league title in 39 years. Rhode Island (10-2, 7-1 Coastal Athletic Association) secured the program's seventh title, with each of the previous six coming in the Yankee Conference. The Rams tied a program record for total wins in a season with 10, first set in 1984 and matched in 1985. Hunter Helms threw for 209 yards with one touchdown and one interception for Rhode Island. Grant also added his first touchdown reception of the season. Grant rushed for 47 yards on the first snap of the second half. He ran for 56 yards on the drive that ended with his 4-yard touchdown catch for a 20-14 lead. An interception by Braden Price on the ensuing Bryant possession set up another Grant rushing touchdown. Bryant scored in the fourth quarter to make it a one-score game, but a 15-play, 72-yard drive ended with a 3-yard touchdown run by Grant. Grant's 13 rushing touchdowns are tied for Rhode Island's single-season record set last season by Ja’Den McKenzie. Brennan Myer threw for 189 yards with two touchdowns and two interceptions for Bryant (2-10, 0-8). Dylan Kedzior rushed for 80 yards and a touchdown, and Landon Ruggieri caught eight passes for 105 yards and a score. Get poll alerts and updates on the AP Top 25 throughout the season. Sign up here . AP college football: https://apnews.com/hub/ap-top-25-college-football-poll and https://apnews.com/hub/college-football50.jili 。

Stubblefield accounts for 4 TDs, South Carolina State runs past Norfolk State 53-21

Mrazek makes 32 saves as the Blackhawks beat the Panthers 3-1

Aurobindo Pharma, through a U.S. subsidiary, has entered into a collaboration and licence agreement with a global pharma major for development of specific products across respiratory therapeutic area and their commercialisation. The financials include an upfront payment of $25 million on the effective date of the agreement. The two entities have agreed to equally share the developmental costs with an overall cap of $90 million for Aurobindo, the Hyderabad-based generic drugmaker said in a filing on Saturday. Citing confidentiality clause in the agreement, it, however, did not disclose the pharma major’s name. The product development is estimated to span 3-5 years. The two entities will co-exclusively commercialise the products to be manufactured at the partner’s facility. The partner will have global manufacturing rights for the codeveloped and commercialised products. Aurobindo has an option to technology transfer at a future date. On rationale and benefits of the agreement, Aurobindo listed sharing of risks associated with product development as well as the cost of development; reduction in the gestational period for developing the product from scratch; and strengthening/ diversification of its existing product portfolio. Published - November 23, 2024 07:05 pm IST Copy link Email Facebook Twitter Telegram LinkedIn WhatsApp Reddit